New data reinforce positive impact of Oncotype DX(R) Genomic Prostate Score(TM)
Genomic Health announced results from two new studies demonstrating the positive impact of the Oncotype DX® Genomic Prostate Score™ test on risk assessment for better treatment decisions in clinically low-risk prostate cancer patients in real-world practice. May 21, 2018